David S. Snyder, MD

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research in myelofibrosis.

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research dedicated to providing more curative options to patients with myelofibrosis.

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses emerging agents in myelofibrosis.

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.